Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness

• Published in: The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 12; no. 10; p. 2732
• Main Authors: Li, Xingnan, Newbold, Paul, Katial, Rohit, Hirsch, Ian, Li, Huashi, Martin, Ubaldo J, Meyers, Deborah A, Bleecker, Eugene R
• Format: Journal Article
• Language: English
• Published: United States 01.10.2024
• Subjects: Adult; Aged; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Asthma - drug therapy; Asthma - physiopathology; Cluster Analysis; Double-Blind Method; Eosinophils - immunology; Female; Humans; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Treatment Outcome; Benralizumab; Heterogeneity; Phenotypic cluster; FEV; Antiasthmatic agents; Vital capacity; Respiratory hypersensitivity; Asthma
• ISSN: 2213-2201
• DOI: 10.1016/j.jaip.2024.04.026

An improved understanding of how severe asthma heterogeneity affects response could inform treatment decisions. Characterize heterogeneity and benralizumab responsiveness in patients grouped by predefined Severe Asthma Research Program clusters using a multivariate approach. In post-hoc analyses of the randomized, double-blind, placebo-controlled phase III SIROCCO (NCT01928771) and CALIMA (NCT01914757) studies, patients with severe asthma who received benralizumab or placebo were assigned to clusters using an established discriminant function to analyze 11 clinical characteristics simultaneously. The annualized asthma exacerbation rate, exacerbation incidence, and lung function were analyzed across clusters. Patients (n = 2,281) met criteria for four of five clusters: cluster 2 (early-onset moderate asthma, n = 393), cluster 4 (early-onset severe asthma, n = 386), cluster 3 (late-onset severe asthma, n = 641), and cluster 5 (late-onset severe, obstructed asthma, n = 861); no patients met cluster 1 criteria. Exacerbation rate reductions were significant in late-onset severe asthma (-48% [95% CI, -61% to -31%]; P < .0001) and late-onset severe, obstructed asthma (-50% [95% CI, -59% to -38%]; P < .0001), with nonsignificant reductions in early-onset clusters. These differences could not be fully explained by blood eosinophil count differences. Values for improvements in FEV were significant in late-onset severe asthma (+133 mL [95% CI, 66-200]; P = .0001) and late-onset severe, obstructed asthma (+160 mL [95% CI, 85-235]; P < .0001) while maintaining acute bronchodilator responsiveness. Benralizumab reduced exacerbations and improved lung function, primarily in late-onset asthma clusters. This multivariate approach to identify subphenotypes, potentially reflecting pathobiological mechanisms, can guide therapy beyond univariate approaches.